Generic pharmaceutical drugs direct purchasers $85M class action settlement

Sun Pharmaceuticals and Taro Pharmaceuticals agreed to pay a combined $85 million class action settlement to resolve claims they worked together to raise and fix the price of certain generic drugs.

The settlement benefits individuals and entities who purchased or paid for certain named generic drugs directly from one or more of the defendants between May 1, 2009, and Dec. 31, 2019. A full list of eligible drugs can be found on the settlement website, along with a full list of the defendants.

Those who purchased these drugs from a retail pharmacy such as Walgreens or CVS are not part of the class.

According to the class action lawsuit, Sun Pharmaceuticals and its affiliates Caraco Pharmaceutical Laboratories Ltd., Mutual Pharmaceutical Co. Inc. and URL Pharma Inc., Taro Pharmaceuticals and other pharmaceutical companies not included in the settlement conspired to raise and fix the price of certain generic drugs. This scheme allegedly caused patients and other payers to pay more for generic drugs than they would have in a competitive market.

Sun Pharmaceuticals and Taro Pharmaceuticals are global pharmaceutical drug manufacturers and developers.

Sun Pharmaceuticals and Taro Pharmaceuticals haven’t admitted wrongdoing but agreed to a $85 million class action lawsuit settlement to resolve the antitrust claims. Sun agreed to pay $17.357 million, and Taro agreed to pay $67.643 million.

Under the terms of the generic drug class action lawsuit settlement, class members can receive a proportional share of the net settlement fund based on the direct purchases they made during the class period. No payment estimates are available at this time.

The deadline for exclusion and objection was Sept. 23, 2022.

The final approval hearing for the generic drug class action lawsuit settlement was held March 8, 2023.

In order to receive a settlement payment, class members must submit a valid claim form postmarked no later than May 6, 2024.

Who’s Eligible

The settlement benefits individuals and entities who purchased or paid for certain named generic drugs directly from one or more of the defendants between May 1, 2009, and Dec. 31, 2019.

A full list of eligible drugs can be found on the settlement website.

Potential Award

Varies

Proof of Purchase

Receipts, account statements and prescription orders showing the class member purchased at least one of the named generic drugs between May 1, 2009, and Dec. 31, 2019, directly from a defendant are required for class members who were not sent a claim form.

Class members may also be required to submit purchase data showing all eligible purchases if such data is not available from the defendants.

Claim Form

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

05/06/2024

Case Name

In re: Generic Pharmaceuticals Pricing Antitrust Litigation, Case No. 2:16-MD-02724, in the U.S. District Court for the Eastern District of Pennsylvania

Final Hearing

03/08/2023

Settlement Website

GenericDrugsDirectPurchaserSettlement.com

Claims Administrator

In re: Generic Pharmaceuticals Pricing Antitrust Litigation – Direct Purchasers
c/o A.B. Data, Ltd.
PO Box 173095
Milwaukee, WI 53217
info@GenericDrugsDirectPurchaserSettlement.com
877-315-0583

Class Counsel

Dianne M Nast
Joseph N Roda
NASTLAW LLC

David F Sorensen
BERGER MONTAGUE PC

Robert N Kaplan
KAPLAN FOX & KILSHEIMER LLP

Thomas M Sobol
HAGENS BERMAN SOBOL SHAPIRO LLP

Linda P Nussbaum
NUSSBAUM LAW GROUP PC

Michael L Roberts
ROBERTS LAW FIRM PA

Defense Counsel

John M Taladay
Erik T Koons
BAKER BOTTS LLP

Erik Zwicker 
TARO PHARMACEUTICALS USA INC